The anti-androgen drug dutasteride renders triple negative breast cancer cells more sensitive to chemotherapy via inhibition of HIF-1α-/VEGF-signaling

  • Marie-Kristin von Wahlde, Carolin Hülsewig, Christian Ruckert, Martin Götte, Ludwig Kiesel, Christof Bernemann
  • Gynecological Endocrinology, October 2014, Taylor & Francis
  • DOI: 10.3109/09513590.2014.971235

The authors haven't finished explaining this publication. If you are the author, sign in to claim or explain your work.

Read Publication

http://dx.doi.org/10.3109/09513590.2014.971235

The following have contributed to this page: Professor Martin Götte